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Introduction
The hyperplastic polyps (HPs)-serrated adenomas (SAs)-adenocarcinoma
(AC) sequence in the colorectal tumorigenic pathway has been
proposed as the different way from the traditional adenoma-
carcinoma sequence suggested by Vogelstein.1-4 HPs are rounded
and usually sessile polypoid lesions of a few millimeters in diame-
ter showing elongated crypts with a tendency to cystic dilatation.
The epithelium of serrated gland in HPs is constituted by a single
layer of cells without the dysplasia such as swollen nuclei and
crowding of nuclei.5 Therefore, it has been believed that HPs are
absolutely benign lesions which lack any malignant potential.
However, recently the case has been reported the occurrence of AC
drived from HP.6 SAs are also flat and/or sessile polypoid lesions
in the endoscopic appearance and demonstrate the histopathological
characteristics of saw-tooth appearance in those glands,7 and it may
be difficult to distinguish between HPs and SAs in the morphol-
ogic spectrum.1 Longacre et al. described that the general architec-
ture of SAs was similar to that of HPs,8 however the cytologic fea-
tures were different since surface mitotic activity, nuclear
pseudostratification, and nuclear/cytoplasmic ratio were greater
than in classic hyperplastic lesions. Although the prevalence of
high grade dysplasia, which could be construed as a measure of
such risk, was reported with 37% SAs containing foci of "signifi-
cant dysplasia" and 11% containing intramucosal carcinoma,8 the
natural history of SAs and their risk for progression to malignancy
is not well understood.
Vascular endothelial growth factor (VEGF) has been identified
as a key regulator of tumor angiogenesis, and VEGF receptors
(VEGFRs) are the major mediators of the mitogenic and perme-
ability-enhancing effects of VEGF in endothelial cells.9 ,10 In addi-
tion, VEGF is a survival factor for endothelial cells and a marked
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AIM: The aim of this study was to investigate the role for vascular endothelial growth factor (VEGF) and its receptors, VEGFR-1 and -2, in
the hyperplastic polyp (HP)- serrated adenoma (SA)-adenocarcinoma (AC) sequence of the colorectum.
Methods: Thirty-six HPs, 33 SAs and 7 ACs (which contained HP and/or SA) were immunohistochemically examined for the expression of
VEGF, VEGFR-1, and VEGFR-2.
Results: VEGF protein was expressed in the cytoplasm of SA and AC tumor cells, and VEGFR-1 and VEGFR-2 were expressed both in the
cytoplasm and on the membrane of these tumors, while there was faint or no expression of VEGF, VEGFR-1 and VEGFR-2 in HPs.
Immunohistochemical staining revealed that 8.3% (3 of 36) HPs, 87.9% (29 of 33) SAs and 100% (7 of 7) ACs were positive for VEGF; 2.8%
(1 of 36) HPs, 97.0% (32 of 33) SAs and 100% (7 of 7) ACs were positive for VEGFR-1; 16.7% (6 of 36) HPs, 100% (33 of 33) SAs and 100%
(7 of 7) ACs were positive for VEGFR-2. The expression of VEGF, VEGFR-1 or VEGFR-2 was statistically correlated with the sequence of HP,
SA and AC (P < 0.0001, respectively)
Conclusion: Our results suggest that the VEGF pathway may play an important role in the HP-SA-AC sequence.
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dependence on VEGF has been shown in newly formed but not es-
tablished tumor vessels.11 Although tumor angiogenesis is an area
of extensive research, the consequence of enhanced angiogenesis and
its reversion on tumor growth and progression are only partially
elucidated.12-14 Recently, coexpression of VEGF and its receptor, ei-
ther VEGFR-1 (Flt-1) or VEGFR-2 (Flk-1/KDR), has been re-
ported in tumor cells, suggesting the presence of an autocrine and/
or a paracrine VEGF/VEGFR growth pathway in solid tumors.15-17
Further, the expression levels of VEGF and VEGFR have been
shown to correlate with progressive tumor growth and develop-
ment of metastasis in many carcinomas.18
The present study aims to evaluate the expression and distribu-
tion of VEGF and VEGFR in HPs, SAs and ACs and to ascertain




The material consisted of 64 paraffin-embedded tissue sections
of colorectal lesions from 64 patients in Nagasaki University
Hospital. The definition of SA was based on the description by
Longacre and Fenoglio-Preiser as follows: a neoplastic lesion com-
posed of a monotonous cell population with atypical nuclei prolif-
erating in a serrated glandular architecture.8 According to the
Vienna classification, we diagnosed tumors in category 5 as carci-
nomas.19 The material consisted of 57 benign solitary polyps and 7
ACs including 6 well differentiated and 1 moderately differentiated
adenocarcinoma. The histopathological differentiation of colorectal
adenocarcinomas determined according to the WHO classification
for tumors. All of the colorectal carcinomas were consisted in SA
and/or HP. Of the solitary polyps, 31 were HPs and 26 were SAs.
Two independent pathologists (M. Taba and T. Nakayama) deter-
mined the diagnosis of HP, SA and AC.
Immunohistochemistry for VEGF and VEGFRs
The subcellular location of VEGF, VEGFR-1 and VEGFR-2
was determined in HPs, SAs and ACs using polyclonal antibodies
directed against unique sequences of these proteins. These antibod-
ies were devoid of any cross-reaction with other proteins in the
VEGF family.20 Formalin-fixed, paraffin-embedded tissues were
cut into 4- m thick sections, deparaffinized in xylene and rehydrated
in PBS. Deparaffinized sections were preincubated with normal
bovine serum to prevent non-specific binding and then incubated
overnight at 4℃ with primary polyclonal antibody to human
VEGF (1 g/ml), VEGFR-1 (Flt-1(C-17), 1mg/L) or VEGFR-2
(Flk-1(C-20), 1 g/ml) (Santa Cruz Biotechnology, Inc, USA), fol-
lowed by alkaline phosphatase-conjugated goat anti-rabbit IgG an-
tibody (0.4 g/ml; Santa Cruz Biotechnology, Inc.). The reaction
products were visualized using a mixture of 5-bromo-4-chloro-3-
indolyl phosphate and nitroblue tetrazolium chloride (BCIP/NBT;
Roche Diagnostic Corp., Indianapolis, IN, USA). Negative controls
consisted of replacing the primary antibody with non-immunized
rabbit serum. Antigen absorption for anti-VEGF, VEGFR-1 and
VEGFR-2 antibody using excess recombinant VEGF, VEGFR-1
and VEGFR-2 in each samples (R&D Systems Europe, MN,
USA), and human breast cancer tissue served as the positive con-
trol.21 VEGF, VEGFR-1 and VEGFR-2 expressions were classified
into 2 categories depending upon the percentage of the cells
stained and/or the intensity of staining (-: 0% to 15% positive
tumor cells; +: >15% positive tumor cells).
Statistical analysis
The Stat View program (Abacus Concepts, Inc., Berkeley, CA,
USA) was used for statistical analysis. Analyses comparing the de-
gree of VEGF, VEGFR-1 or VEGFR-2 expressions in HPs, SAs
and ACs were performed using Kruskal-Wallis test.
Results
Figure 1 shows a case with AC (1C) complicated with HP (1A)
and SA (1B). Figure 2, 3 and 4 demonstrated the results of
immunohistochemical staining for VEGF, VEGF-1 and VEGFR-2
in HP, SA and AC, respectively. VEGF, VEGFR-1 and VEGFR-2
expressions were heterogenous in SAs (Figure 3) and ACs (Figure
4), and localized to the cytoplasm and/or cell membrane of tumor
cells, while the expression of these proteins was not detected in HP
cells (Figure 2) in the specimens of AC with HP and/or SA.
Immunohistochemical staining further revealed VEGF expression
in the cytoplasm of SA (Figure 3B) and AC (Figure 4B) cells.
VEGFR-1 expression was shown in the membrane and cytoplasm
of SA (Figure 3C) and AC (Figure 4C) cells. VEGFR-2 was ex-
pressed in the membrane and cytoplasm of SA (Figure 3D) and AC
(Figure 4D) cells. However, in HP cells, there was faint or almost
no positive staining of VEGF (Figure 2B), VEGFR-1 (Figure 2C),
and VEGFR-2 (Figure 2D). Immunohistochemical staining was
positive for VEGF in 8.3% (3 of 36) HP, 87.9% (29 of 33) SA and
100.0% (7 of 7) AC. Positive staining for VEGFR-1 was detected
in 2.8% (1 of 36) HP, 97.0% (32 of 33) SA and 100% (7 of 7) AC.
Immunohistochemical staining was positive for VEGFR-2 in 16.7%
(6 of 36) HP, 100% (33 of 33) SA and 100% (7 of 7) AC. There
were statistical correlations in the expressions of VEGF, VEGFR-1 or
VEGFR-2 between the sequence of HP, SA and AC (P < 0.0001).
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Table. VEGF, VEGFR-1 and VEGFR-2 expression in HP, SA and AC. n (%)
VEGF* VEGFR-1* VEGFR-2*

























*; p<0.0001, Kruskal-Wallis test.
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Discussion
The more prevalent cancers of the traditional adenoma-carcinoma
sequence accounted for upwards of two-thirds of all colorectal can-
cers.22,23 These originate in adenomas (or aberrant crypt foci) insti-
gated by mutations of the APC or -catenin gene that lead to dis-
ruption of the Wnt signaling pathway, and the end point
carcinomas are frequently characterized by chromosomal instabil-
ity.24 ,25 As the traditional adenoma-carcinoma sequence, the HP-
SA-AC sequence was accounted for genetic abnormalities. In the
HP-SA-AC sequence, deoxyribonucleic acid (DNA) mismatch re-
pair resulting in microsatellite instability (MSI) plays an important
role,5 however, they also include some proportion of carcinomas
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Figure 1. Hematoxylin and eosin staining of a case with AC (1C) compli-
cated with HP (1A) and SA (1B).
Figure 2. Hematoxylin and eosin staining of HP (A). Immunohistochemical
staining of HP with antibodies to VEGF (B), VEGFR-1 (C) and VEGFR-2
(D). VEGF, VEGFR-1 and VEGFR-2 expressions were not detected in the
epithelium of HP (B, C, and D). (magnification: x 400)
Figure 3. Hematoxylin and eosin staining of SA (A). Immunohistochemical
staining reveals VEGF expression in cytoplasms of the epithelium of SA
(B); VEGFR-1 and VEGFR-2 expression in the membrane and cytoplasms
of epithelium of SA (C and D).
Figure 4. Hematoxylin and eosin staining of AC (A). Immunohistochemical
staining reveals VEGF expression in cytoplasms of the epithelium of AC
(B); VEGFR-1 and VEGFR-2 expression in the membrane and cytoplasms
of the epithelium of AC (C and D).
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that are microsatellite stable (MSS).22 The penultimate stage in the
progression to carcinoma in this pathway is likely to be SA.26
Recently, angiogenesis, or the development of a vascularised
stroma, is essential for tumors to grow beyond a minimal size27 ,28
and metastasis.29,30 In support of this hypothesis, expression of
VEGF has been shown to correlate positively with microvessel
count and metastasis.31 In our study, there were no significant dif-
ferences between vessel counts and the VEGF, VEGFR-1, and
VEGFR-2 expression (data not shown). The reason of this remains
unclear, however, there is strong evidence that the VEGF/VEGFR
pathway has tumor growth and progression effects, which are
angiogenesis-independent manners.
It was previously reported that the angiogenic switch occurs at
the adenoma stage of the adenoma-carcinoma sequence in colorec-
tal cancer.32 VEGF and tissue factor were correlated in the early
stages of the development of colorectal cancer. In this study,
VEGF was higher expressed in SAs and ACs than in HPs. From
these results, we concluded that the expression of VEGF might be
activated in the adenoma stage of both the adenoma-carcinoma and
the HP-SA-AC sequences. The production of VEGF, which began
during the step of adenoma or SAs, may contribute to the progres-
sion and/or growth of colorectal cancer.
The coexpression of VEGF with VEGFR-1 and -2 has been re-
ported in tumor cells, suggesting the presence of an autocrine and/-
or paracrine VEGF/VEGFR growth pathway in solid tumors.15-17 ,20
VEGF has already been shown to play a role in the colorectal ACs.33
However, there have been no studies on VEGF and VEGFR ex-
pressions in the HP-SA-AC sequence. Our data show that the ex-
pressions of VEGF and VEGFR were significantly elevated in ACs
and SAs compared with HPs. Moreover, expressions of VEGF and
VEGFRs were detected in the lesions of SAs and ACs, although
these proteins were minimally detected in the lesions of HPs.
These data suggest that the VEGF/VEGFR pathway may play an
important role in the HP-SA-AC sequence.
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